APP and Alzheimer disease: In addition to these previously reported changes, 19,20-diHDoPE and 17,18-diHETE, the stable metabolites of 19,20-EpDPE and 17,18-EpETE that have a potential counteracting role for AD, were increased in APP/tau brain tissue at the pre-symptomatic phase, and concomitant increases in plasma were observed.